TY  - GEN
AU  - Yamaguchi,Hiromi
AU  - Shimatsu,Akira
AU  - Okayama,Akifumi
AU  - Sato,Takahiro
TI  - Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance
SN  - 1348-4540
PY  - 2020///1207
KW  - Acromegaly
KW  - drug therapy
KW  - Adenoma
KW  - complications
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents, Hormonal
KW  - therapeutic use
KW  - Bromocriptine
KW  - Cabergoline
KW  - Chemical and Drug Induced Liver Injury
KW  - epidemiology
KW  - Child
KW  - Disease Progression
KW  - Dopamine Agonists
KW  - Drug Therapy, Combination
KW  - Female
KW  - Growth Hormone-Secreting Pituitary Adenoma
KW  - Human Growth Hormone
KW  - analogs & derivatives
KW  - Humans
KW  - Hypoglycemia
KW  - chemically induced
KW  - Insulin-Like Growth Factor I
KW  - metabolism
KW  - Japan
KW  - Male
KW  - Middle Aged
KW  - Neurosurgical Procedures
KW  - Octreotide
KW  - Peptides, Cyclic
KW  - Product Surveillance, Postmarketing
KW  - Radiotherapy
KW  - Receptors, Somatotropin
KW  - antagonists & inhibitors
KW  - Somatostatin
KW  - Tumor Burden
KW  - Young Adult
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1507/endocrj.EJ19-0266
ER  -